PR View by Gil Bashe

Share this article:
Treating rare disorders was once considered a "good-will science endeavor," but market forces have encouraged companies to revisit how these small molecules can be big business, and researchers are finding that therapeutic applications for one rare disease area often holds promise in others. Gleevec and Enbrel are members of the billion dollar club once reserved for allergy drugs and antidepressants.

Orphan-drug companies face a Herculean task: raising visibility among needle-in-a-haystack groups. Orphan drug populations typically number less than 200,000, while an “ultra-orphan” drug can treat fewer than 10,000. Reaching out requires transcending the bias that these are minor illnesses—they're colossal to patients.

Small patient populations have their own patient groups and advocacy programs, where communities learn about treatments, interact with members and attend virtual meetings. Groups offer information on experimental therapies and provide R&D updates.

New media also plays a big role in outreach efforts. While blogs can be an important target alongside traditional media, they create compliance challenges. Orphan communities change the rules for adverse-event reporting. Some manufacturers may not want to take on the responsibility. Patients exchanging personal views online may not want opinions shared with a company. Snooping in sensitive areas can damage relationships.

Social networking offers opportunities to interact directly with focused audiences. Web video offers an intimacy unmatched by other communication channels. For patients whose are very motivated to find information, an aggressive, Web 2.0-focused campaign may be appropriate, integrating viral tactics with traditional PR.

Gil Bashe is EVP, health practice, Makovsky + Co.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?